Next Article in Journal
NLRP3 Activation and Its Relationship to Endothelial Dysfunction and Oxidative Stress: Implications for Preeclampsia and Pharmacological Interventions
Previous Article in Journal
A New Induction Method for the Controlled Differentiation of Human-Induced Pluripotent Stem Cells Using Frozen Sections
Previous Article in Special Issue
Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
Article

Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery

1
Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, 3010 Bern, Switzerland
2
Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
3
Department of Congenital and Pediatric Heart Surgery, German Heart Center Munich, Technische Universität München, 80636 Munich, Germany
4
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
5
Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsmedizin Rostock, 18057 Rostock, Germany
6
Department of Endocrinology and Metabolic Medicine, Divison of Lipid Metabolism, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany
7
Department of Cardiology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland
*
Author to whom correspondence should be addressed.
Equally contributing first authors.
Academic Editors: Tania Garfias-Veitl and Stephan von Haehling
Cells 2021, 10(11), 2829; https://doi.org/10.3390/cells10112829
Received: 20 August 2021 / Revised: 8 October 2021 / Accepted: 19 October 2021 / Published: 21 October 2021
(This article belongs to the Special Issue Understanding Biomarkers in Cardiology)
Altered lipid metabolism has been shown to be of major importance in a range of metabolic diseases, with particular importance in cardiovascular disease (CVD). As a key metabolic product, altered lipoprotein(a) (Lp(a)) levels may be associated with adverse clinical outcomes in high-risk cardiovascular patients undergoing cardiac surgery. We aimed to investigate the impact of the important metabolite Lp(a) on complications and clinical outcomes in high-risk patients. A prospective observational cohort study was performed. Data were derived from the Bern Perioperative Biobank (ClinicalTrials.gov NCT04767685), and included 192 adult patients undergoing elective cardiac surgery. Blood samples were collected at 24 h preoperatively, before induction of general anaesthesia, upon weaning from cardiopulmonary bypass (CPB), and the first morning after surgery. Clinical endpoints included stroke, myocardial infarction, and mortality within 30 days after surgery or within 1 year. Patients were grouped according to their preoperative Lp(a) levels: <30 mg/dL (n = 121; 63%) or >30 mg/dL (n = 71, 37%). The groups with increased vs. normal Lp(a) levels were comparable with regard to preoperative demographics and comorbidities. Median age was 67 years (interquartile range (IQR) 60.0, 73.0), with median body mass index (BMI) of 23.1 kg/m2 (23.7, 30.4), and the majority of patients being males (75.5%). Over the observational interval, Lp(a) levels decreased in all types of cardiac surgery after CPB (mean decline of approximately −5 mg/dL). While Lp(a) levels decreased in all patients following CPB, this observation was considerably pronounced in patients undergoing deep hypothermic circulatory arrest (DHCA) (decrease to preoperative Lp(a) levels by −35% (95% CI −68, −1.7), p = 0.039). Increased Lp(a) levels were neither associated with increased rates of perioperative stroke or major adverse events in patients undergoing cardiac surgery, nor with overall mortality in the perioperative period, or at one year after surgery. Other than for cohorts in neurology and cardiology, elevated Lp(a) might not be a risk factor for perioperative events in cardiac surgery. View Full-Text
Keywords: cardiovascular disease; lipoprotein(a); cardiac surgery; cardiopulmonary bypass cardiovascular disease; lipoprotein(a); cardiac surgery; cardiopulmonary bypass
Show Figures

Figure 1

MDPI and ACS Style

Heinisch, P.P.; Mihalj, M.; Huber, M.; Schefold, J.C.; Hartmann, A.; Walter, M.; Steinhagen-Thiessen, E.; Schmidli, J.; Stüber, F.; Räber, L.; Luedi, M.M. Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery. Cells 2021, 10, 2829. https://doi.org/10.3390/cells10112829

AMA Style

Heinisch PP, Mihalj M, Huber M, Schefold JC, Hartmann A, Walter M, Steinhagen-Thiessen E, Schmidli J, Stüber F, Räber L, Luedi MM. Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery. Cells. 2021; 10(11):2829. https://doi.org/10.3390/cells10112829

Chicago/Turabian Style

Heinisch, Paul P., Maks Mihalj, Markus Huber, Joerg C. Schefold, Alexander Hartmann, Michael Walter, Elisabeth Steinhagen-Thiessen, Juerg Schmidli, Frank Stüber, Lorenz Räber, and Markus M. Luedi 2021. "Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery" Cells 10, no. 11: 2829. https://doi.org/10.3390/cells10112829

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop